BPC-157 is a fifteen-amino-acid synthetic peptide derived from a protein in human gastric juice, studied in rodent models for tendon, ligament and gut tissue repair through proposed angiogenic and anti-inflammatory pathways. Human clinical data is sparse. On 23 July 2026 an FDA advisory committee voted 8-6 with one abstention to recommend it for pharmacy compounding, against the advice of FDA's own reviewers, who said the peptide is not well-characterised enough to set quality standards for. That vote does not make it legal to compound. Across 68 third-party-tested vials we hold, median purity is 99.92%, but one vial came back at 46.85%.
Research notes
BPC-157 is the most-discussed peptide in the recovery market and one of the least-characterised. It is fifteen amino acids long, derived from a fragment of a protein found in human gastric juice, and studied almost entirely in rodents. In July 2026 an FDA advisory committee narrowly recommended it for pharmacy compounding, over the objection of FDA's own scientists, who said they do not know enough about the molecule to write a specification for it.
Both of those things are true at once, and holding them together is the honest read on this compound.
How does BPC-157 work?
BPC-157 is a synthetic pentadecapeptide corresponding to a partial sequence of body protection compound, a protein isolated from gastric juice. The mechanism remains under investigation.
The pathway most consistently reported is angiogenesis, the formation of new blood vessels at an injury site, with proposed involvement of VEGF-receptor signalling. Secondary reported effects include upregulation of growth-factor receptors in healing tissue and broad anti-inflammatory activity. Studies have covered tendon, ligament, muscle, bone and intestinal injury models.
What holds this together is a repair-signalling story rather than a single receptor. What it lacks is a defined molecular target, which is precisely the gap FDA reviewers pointed at.
What doses appear in the research?
Rodent protocols most often use around 10 μg/kg, administered intraperitoneally or orally. Studies run days to weeks depending on the injury model.
The number circulating in the research market, 250 to 500 mcg daily over 4 to 8 week cycles, does not come from a published human trial. It is a conversion of animal dosing into a human-scale figure. Anyone presenting it as an established protocol is presenting an extrapolation as a finding.
What did the July 2026 FDA vote do?
On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend BPC-157 for the 503A Bulks List, nominated for ulcerative colitis. BPC-157 had already been removed from the Category 2 do-not-compound list in April 2026.
FDA's own review staff had recommended against it. Their stated grounds were a lack of evidence supporting effectiveness for the nominated indication, and that the substance is not well-characterised, so the agency cannot establish quality standards for it. Read that second point carefully. It is not a claim that BPC-157 is dangerous. It is a claim that FDA does not currently know enough about what the molecule is to specify what an acceptable batch would look like.
None of this made BPC-157 legal to compound. Category 2 removal does not confer eligibility, and an advisory recommendation is not a rule. Notice-and-comment rulemaking is expected to run into 2027 or beyond unless FDA grants interim Category 1 status. The mechanics are in our FDA peptide vote explainer, and none of it changes anything for research-grade material sold online.
How pure is the BPC-157 on the market?
We mirror third-party certificates rather than repeating vendor claims. BPC-157 is the most-tested compound in our Kovera corpus.
Across 68 BPC-157 certificates issued by Kovera Labs, covering 43 vendors, certified between 11 January and 10 June 2026 and retrieved from Kovera's verifier on 2 August 2026:
| Measure | Value |
|---|---|
| Records | 68 |
| Distinct vendors | 43 |
| Median purity | 99.92% |
| Highest purity | 99.98% |
| Lowest purity | 46.85% |
| Records below 98% | 1 |
| Identity confirmation failures | 0 |
| Vials under labelled content | 0 of 64 measured |
Sixty-seven of sixty-eight vials were excellent. One was not. Certificate KVR-2026-E91AD0, issued to Axon Peptide on 20 May 2026, recorded 46.85% purity and was flagged by the lab. The vial contained 5.64 mg of material against a 5 mg label, so it was not short on mass. Roughly half that mass was something other than BPC-157.
That is the argument for checking certificates rather than assuming a category is safe. A 1-in-68 failure rate is low, and it is not zero, and the distribution is not gentle. The gap between the worst vial and the second-worst is more than fifty percentage points. Run any certificate through our COA verifier, which checks it against the issuing lab's own record rather than the vendor's copy of it.
BPC-157 also appears in blends more than any other compound we track, with 62 BPC-157 and TB-500 combination certificates in the same corpus. Blends are harder to verify, for reasons covered below.
Should you buy BPC-157 as a blend?
It is sold constantly as one half of a BPC-157 and TB-500 pair, and as a component of the four-peptide KLOW blend alongside KPV and GHK-Cu.
A blend collapses several identity checks into one. A single purity figure on a multi-component vial tells you what fraction of the contents is not impurity, not whether each named compound is present at its stated amount. We have seen pre-mixed blends certify above 99.8% purity while failing dose and identity confirmation. The detail is in our KLOW stack research read.
Single-compound vials are materially easier to verify.
What this means
BPC-157 has a large, consistent, and almost entirely preclinical evidence base, a mechanism described in terms of pathways rather than targets, and a regulatory file where the agency's own scientists say the characterisation is incomplete. It also tests clean the overwhelming majority of the time, with a tail risk that is severe when it lands.
The July vote changed the compound's political position, not its evidence and not its legal status. Treat any vendor describing BPC-157 as FDA-backed or newly cleared as having told you something useful about the vendor.
Related reading
- FDA peptide vote 2026 - the full vote breakdown and what still stands between a recommendation and legal compounding.
- TB-500 - the compound BPC-157 is most often blended with, and its own testing record.
- KPV - recommended on the same day, the cleanest compound in our corpus.
- GHK-Cu - the fourth KLOW component, off the do-not-compound list but never voted on.
- KLOW stack research read - why pre-mixed blends resist verification.
- What 1,816 Kovera COAs reveal - the corpus behind these figures.
What it's researched for
- tendon and soft-tissue repair research
- gut and intestinal healing research
- angiogenesis research
Where to source it
ALL 16 VENDORS →RANKED BY COMPOSITE SCORE · PRICES ARE SNAPSHOTS FROM THE PRICE INDEX · PER-MG IS A WITHIN-COMPOUND COMPARATOR
Frequently asked about BPC-157
What is BPC-157?
BPC-157 is a 15-amino-acid synthetic peptide derived from a fragment of body protection compound, a protein found in human gastric juice. It is among the most-discussed compounds in the recovery and biohacking community, with published research concentrated on tendon, ligament and gut-tissue repair in rodent injury models.
Is BPC-157 FDA approved?
No. BPC-157 is not approved for any human indication anywhere. On 23 July 2026 the FDA Pharmacy Compounding Advisory Committee voted 8-6 with one abstention to recommend adding it to the 503A Bulks List for ulcerative colitis. That is an advisory recommendation, not approval and not a rule. Compounding it remains outside FDA's enforcement discretion policy.
Why did FDA scientists oppose BPC-157?
Agency reviewers cited a lack of evidence supporting effectiveness for the nominated indication and stated that the substance is not well-characterised, meaning FDA cannot establish quality standards for it without further information. That is a manufacturing-controls objection as much as a clinical one. The advisory committee voted to recommend it regardless.
How does BPC-157 work?
The mechanism is not fully characterised. Preclinical research points to angiogenesis promotion, meaning the formation of new blood vessels at injury sites, together with upregulation of growth-factor receptors and anti-inflammatory signalling. Nearly all published evidence comes from rodent models rather than human clinical trials.
What doses are used in BPC-157 research?
Rodent studies most often use around 10 μg/kg. The figure circulating in the research market, 250 to 500 mcg daily across 4 to 8 week cycles, is an extrapolation from that animal work rather than a published human protocol. Oral administration appears in some studies but bioavailability data is limited.
What is the typical purity of research-grade BPC-157?
Across 68 Kovera-certified vials from 43 vendors, certified between January and June 2026, median purity was 99.92% and no vial fell short of its labelled content. The exception matters though: one certificate recorded 46.85% purity, flagged by the lab, which means roughly half the material in that vial was not BPC-157.